Latest & greatest articles for Galantamine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Galantamine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Galantamine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Galantamine

1. Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study Full Text available with Trip Pro

Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study Donepezil, rivastigmine and galantamine are popular cholinesterase inhibitors used to manage the symptoms of Alzheimer disease and other dementias; regulatory agencies in several countries warn about a possible risk of rhabdomyolysis with donepezil, based on information from case reports. Our goal was to investigate the 30-day risk of admission to hospital with rhabdomyolysis (...) associated with initiating donepezil versus other cholinesterase inhibitors.We conducted a retrospective cohort study in Ontario, Canada, from 2002 to 2017. Participants were adults aged 66 years or older with a newly dispensed prescription for donepezil compared with rivastigmine or galantamine. The primary outcome was hospital admission with rhabdomyolysis (assessed using hospital diagnostic codes) within 30 days of a new prescription of a cholinesterase inhibitor. Odds ratios were estimated using

2019 EvidenceUpdates

2. Pharmacological aspects of galantamine for the treatment of Alzheimer's disease Full Text available with Trip Pro

Pharmacological aspects of galantamine for the treatment of Alzheimer's disease 28337117 2018 11 13 1611-2156 16 2017 EXCLI journal EXCLI J Pharmacological aspects of galantamine for the treatment of Alzheimer's disease. 35-39 10.17179/excli2016-820 Kim Jae Kwang JK Division of Life Sciences, College of Life Sciences and Bioengineering, Incheon National University, Incheon, 406-772, Korea. Park Sang Un SU Department of Crop Science, Chungnam National University, 99 Daehak-ro, Yuseong-gu

2017 EXCLI journal

3. Adverse effects of galantamine, topiramate and cotrimoxazole

Adverse effects of galantamine, topiramate and cotrimoxazole Prescrire IN ENGLISH - Spotlight ''In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole'', 1 July 2015 {1} {1} {1} | | > > > In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |  (...)  |   |   |  Spotlight In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole FREE DOWNLOAD All in one sample page: from serious skin reactions with Alzheimer's drug galantamine and visual field defects with topiramate to the potentially deadly effects of the antibiotic cotrimoxazole, either alone or when coadministrered with an ACE inhibitor or ARB. Sample page available for free download. Cotrimoxazole + an ACE inhibitor

2015 Prescrire

4. Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease. Full Text available with Trip Pro

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease. Several studies have tested the N-methyl-D-aspartate-receptor antagonist memantine as an add-on to pre-existing treatment with acetylcholinesterase inhibitors. The objective of this study was to evaluate the efficacy and safety of a combined memantine and galantamine-CR de novo regimen compared with galantamine-CR only treatment (...) in never treated patients with mild-to-moderate Alzheimer's disease (AD).Antidementia drug-naïve participants (n = 232) with probable, mild-to-moderate AD, and mini-mental state examination scores between 15 and 26 (inclusive) were randomized to receive either 20 mg/day memantine plus 24 mg/day galantamine-CR or 24 mg/day galantamine-CR plus placebo in a 52-week, prospective, double-blind, controlled trial. The primary outcome measurement was the change on the Alzheimer's disease assessment scale

2015 Alzheimer's & dementia (New York, N. Y.) Controlled trial quality: predicted high

5. [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine]

[Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine] Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine] Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin [Cholinesterase inhibitors in Alzheimer's disease - supplementary (...) commission: rivastigmine patches and galantamine] IQWiG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin. [Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine] Cologne: Institut fuer

2012 Health Technology Assessment (HTA) Database.

6. Cholinesterase inhibitors in Alzheimer's disease: supplementary commission rivastigmine patches and galantamine

Cholinesterase inhibitors in Alzheimer's disease: supplementary commission rivastigmine patches and galantamine Executive Summary 1 Translation of the executive summary of the final report “Cholinesterasehemmer bei Alzheimer Demenz: Ergänzungsauftrag Rivastigmin-Pflaster und Galantamin” (Version 1.0; Status: 03.02.2012). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. IQWiG Reports - Commission No. A09-05 Cholinesterase inhibitors in Alzheimer’s disease: supplementary commission rivastigmine patches and galantamine 1 Executive summary of final report A09-05 Version 1.0 Cholinesterase inhibitors – rivastigmine patches/galantamine 03.02.2012 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Cholinesterase inhibitors in Alzheimer’s disease: supplementary

2012 Institute for Quality and Efficiency in Healthcare (IQWiG)

7. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer&#39

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer' Overview | Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | Guidance | NICE Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance [TA217] Published date: 23 March 2011 Last updated: 20 June 2018 Share Save Guidance on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (...) (Ebixa) for treating Alzheimer's disease in adults. This guidance has been partially updated by NICE’s guideline on (NG97) and replaces NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111). Guidance development process Is this guidance up to date? . We identified nothing new that affects recommendations 1.1, 1.2, 1.4, 1.5 and 1.6. Recommendation 1.3 was updated in June 2018 in NICE’s guideline on dementia (NG97

2011 National Institute for Health and Clinical Excellence - Technology Appraisals

8. Efficacy and safety of galantamine hydrobromide in the treatment of mild to moderate dementia Full Text available with Trip Pro

Efficacy and safety of galantamine hydrobromide in the treatment of mild to moderate dementia Efficacy and safety of galantamine hydrobromide in the treatment of mild to moderate dementia Efficacy and safety of galantamine hydrobromide in the treatment of mild to moderate dementia Oremus M, Santaguida P, Raina P CRD summary The review concluded that galantamine was superior to placebo in patients with dementia after a maximum six-month follow-up. There was no evidence of a benefit compared (...) with donepezil. The authors stated that the evidence needed careful interpretation and further research was needed. Data limitations and potential review biases mean that the authors' recommendation to interpret the evidence carefully is appropriate. Authors' objectives To determine the efficacy and safety of galantamine hydrobromide in the treatment of mild to moderate dementia. Searching EMBASE, CINAHL, AgeLine, PsycINFO, MEDLINE, PREMEDLINE, AMED and Cochrane Central Register of Controlled Trials (CENTRAL

2010 DARE.

9. Galantamine for dementia in people with Down syndrome. (Abstract)

Galantamine for dementia in people with Down syndrome. Alzheimer's dementia (AD) is the most common form of dementia in people with Down Syndrome (DS). Acetylcholine is a chemical found in the brain that has an important role in memory, attention, reason and language. Galantamine both inhibits the activity of acetylcholinesterase and increases the level of acetylcholine. Galantamine can improve cognitive function and slow the decline of AD in the general population over time. It is important (...) to note that people with DS tend to present with AD at a much younger age than the normal population as well as having subtle differences in physiology (e.g. metabolism and heart rate) and may therefore have different requirements from the general population.To determine the effectiveness and safety of galantamine for people with DS who develop AD.CENTRAL, MEDLINE, EMBASE, CINAHL, PsycINFO, BIOSIS, SCI, SSCI and the NRR were searched up to October 2008. We contacted the manufacturers of galantamine

2009 Cochrane

10. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine

Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

11. Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea Full Text available with Trip Pro

Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea Suh GH Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to determine the cost-effectiveness of including galantamine in the treatment of mild-to-moderately severe Alzheimer’s disease, compared with usual care. The authors concluded that usual care plus galantamine was cost-effective compared with usual care alone. The methods were appropriate and both the methods and results were reported adequately

2009 NHS Economic Evaluation Database.

12. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE CRD (...) summary This review concluded that cholinesterase inhibitors (donepezil, galantamine and rivastigmine) were able to stabilise or slow decline in cognition, function, behaviour and global change when compared with placebo. There was no clear evidence to determine whether one of these drugs was more efficacious than another. The review was generally well conducted and the conclusions are likely to be reliable. Authors' objectives To assess the efficacy and safety of cholinesterase inhibitors (donepezil

2008 DARE.

13. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technology Assessment 2006; 10(1): 1-176 Authors' objectives The objective of this review was to provide an update review of the best quality evidence for the clinical effectiveness and cost

2006 Health Technology Assessment (HTA) Database.

14. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 111. 2006 Authors' objectives This guidance constitutes a review of 'NICE technology appraisal guidance 19' on the use of donepezil, galantamine and rivastigmine for the treatment of mild to moderately

2006 Health Technology Assessment (HTA) Database.

15. Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease Full Text available with Trip Pro

Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease Article Text Therapeutics Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease Free James Warner

2005 Evidence-Based Mental Health

16. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis

A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

17. Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries

Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries Caro J, Salas M, Ward A, Getsios D (...) , Migliaccio-Walle K, Garfield F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Galantamine was compared with placebo for the treatment of Alzheimer's disease in seven health care systems. Type of intervention Treatment. Economic study

2004 NHS Economic Evaluation Database.

18. Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial. Full Text available with Trip Pro

Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial. There is no established pharmacological treatment for the core symptoms of chronic fatigue syndrome (CFS). Galantamine hydrobromide, an acetyl cholesterone inhibitor, has pharmacological properties that might benefit patients with CFS.To compare the efficacy and tolerability of galantamine hydrobromide in patients with CFS.Randomized, double-blind trial conducted June 1997 through July 1999 at 35 (...) outpatient centers in the United Kingdom (n = 17), United States (n = 14), the Netherlands (n = 2), Sweden (n = 1), and Belgium (n = 1) involving 434 patients with a clinical diagnosis of CFS (modified US Centers for Disease Control and Prevention criteria).A total of 89 patients were randomly assigned to receive 2.5 mg of galantamine hydrobromide; 86 patients, 5.0 mg; 91 patients, 7.5 mg; and 86 patients, 10 mg (these patients received medicine in the tablet form 3 times per day); a total of 82 patients

2004 JAMA Controlled trial quality: predicted high

19. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK

Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 NHS Economic Evaluation Database.

20. Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia

Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Fajemisin B Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Fajemisin B. Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia. London: Bazian Ltd (Editors), Wessex Institute for Health Research and Development, University of Southampton 2002: 9 Authors' objectives This study aims to assess the effects of acetylcholinesterase inhibitors (donepezil, rivastigmine, tacrine, galantamine) on functional outcomes in people with non-Alzheimer's dementia. Authors' conclusions We found

2002 Health Technology Assessment (HTA) Database.